PICO 7 vs PICO 14 in Revision Hip and Revision Knee Surgery.

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorRobert Jones and Agnes Hunt Orthopaedic and District NHS Trust

About this trial

This is a single-site trial, and it has been designed to compare a revision hip cohort with a revision knee cohort. All consecutive eligible patients, under the care of participating Co-Investigator Orthopaedic Surgeons, are approached for recruitment into the study.

Eligible patients wishing to participate must require either revision hip or revision knee surgery and consent to be randomised to either NPWT PICO dressing for 7-day therapy (PICO 7) or NPWT PICO 14-day therapy (PICO 14).

82 Revision Hips and 82 Revision Knee participants, with 41\* of each cohort randomised to either a 7-day or a 14-day NPWT dressing treatment duration period. The 7-day cohort will be treated with PICO7 dressings and pumps, and the 14-day cohort will be treated with PICO14 dressings.

\*Randomisation will be stratified, so it will continue until there are at least 41 participants in each cohort.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Subjects must be over the age of 18 years.

Participants undergoing aseptic revision hip or aseptic revision knee surgery procedure (a single stage revision procedure).

Participants must be willing and be able to make all the required study visits to be seen by the research team at the Outpatients department at RJAH.

Participants must be able to follow instructions.

Disqualifiers

Revisions for infection, where the nature of the infection has a significant influence on the wound healing, discharge, and length of stay.

Subjects with a history of poor compliance with medical treatment.

Subjects with contraindications (as per the PICO Instructions for use) or hypersensitivity to the use of the NPWT PICO dressing product or its components e.g.: silicone adhesives, polyurethane films, acrylic adhesives, polyethylene fabrics and super- absorbent powders (polyacrylates) contained within the dressing.

Trial design

Design model

Parallel

Treatments tested in this trial

  • PICO 7

    Device

    Participant will receive 7 days of NPWT following revision hip or revision knee surgery.

  • PICO 14

    Device

    Participant will receive 14 days of NPWT following revision hip or revision knee surgery.

Treatment groups

164 Participants
are divided into 2 treatment groups
Group A: Revision Hip surgeryExperimental treatment 2 interventions
Group B: Revision knee surgeryActive comparator 2 interventions

Trial outcomes

Primary outcomes

1

The extent of wound exudate graded 1-4. This is measured by the extent of staining on the dressing at 1-week post-surgery (both study and control groups) and 2 weeks post-surgery (study group only).

The extent of wound exudate graded 1-4 (measured by the extent of staining on the dressing) at 1 week and 2 weeks at follow up appointments. Grading of wound exudate levels and the amount of exudate on the coverage of the dressing: Grade 0 None No staining Grade 1 Light \< 25% Grade 2 Moderate 25% to 50% Grade 3 Heavy 50% to 75% Grade 4 Overt \> 75%

Time frame
Within the first 2 weeks post-surgery
2

Late wound dehiscence or wound discharge (discharge from the wound once the PICO dressing has been discontinued).

If there is any wound discharge after the PICO has been discontinued as per the protocol. The duration of wound discharge (any patients experiencing persistent discharge beyond 48 hrs will be brought back to clinic and dealt appropriately as per the Consultants preferred management methods). If there is any wound dehiscence or breakdown (patients will be brought back to clinic and again, dealt appropriately as per consultants preferred wound management method). The management of persistent wound discharge may require hospitalisation, wound washout or continued and/or prolonged use of a PICO dressing. These are all part of the standard of care at RJAH, but their use does vary slightly, depending on individual preferences of the supervising Surgeon.

Time frame
For the study duration, up to 6 weeks post-surgery.
3

Observance of the formation of wound complications, specifically superficial wound infection, and deep wound infection.

The number of wound complications, specifically concerning superficial wound infections and deep wound infections. The patient will be monitored at 1 week (clinic visit), 2 week (clinic visit), 3 week (phone call), and 6 weeks (clinic visit).

Time frame
For the study duration, up to 6 weeks post-surgery.

Secondary outcomes

1

Wound appearance documented by photographs from before the dressing is applied in theatre to 6 weeks post-surgery follow up visit.

The appearance of the wound at the 1-week clinic visit, where the dressing is changed or PICO therapy discontinued, depending on the treatment arm that the patient has been randomised to, the 2-week clinic visit, where the "study" cohort of patients will have their second dressing removed and at the 6-week clinic visit. The evidence of the wound appearance at these time points will be documented through photographs.

Time frame
For the study duration, up to 6 weeks post-surgery.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.